Asset Details
Do you wish to reserve the book?
Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
Do you wish to request the book?
Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
2023
Overview
Aims/Introduction Selenoprotein P (SeP; encoded by SEPP1 in humans) is a hepatokine that causes impaired insulin secretion and insulin resistance. Metformin downregulates SELENOP promoter activity through an adenosine monophosphate‐activated kinase–forkhead box protein O3a pathway in hepatocytes. This study aimed to test our hypothesis that circulating SeP levels are associated with the glucose‐lowering effect of metformin in humans. Materials and Methods A total of 84 participants with poorly controlled type 2 diabetes were randomly assigned to receive metformin (1,000 mg, twice daily) or a dipeptidyl peptidase‐4 inhibitor, alogliptin (25 mg, once daily) for 12 weeks. We tested metformin and alogliptin on SeP levels and factors associated therewith as a post‐hoc analysis. Results Both metformin and aloglipitin did not change the SeP levels. Although metformin significantly increased the insulin secretory index secretory units of islets in transplantation only in participants with higher baseline SeP (>3.87), both agents similarly reduced fasting plasma glucose and glycated hemoglobin. SeP levels at baseline were correlated negatively with changes in SeP (r = −0.484, P = 0.004) and fasting plasma glucose (r = −0.433, P = 0.011), and positively with changes in C‐peptide immunoreactivity (r = 0.420, P = 0.017) and secretory units of islets in transplantation (r = 0.388, P = 0.028) in the metformin, but not alogliptin, group. Conclusions Higher baseline levels of SeP significantly predicted metformin‐mediated, but not alogliptin‐mediated, glucose‐lowering and insulinotropic effects. Serum SeP levels might be a novel biomarker for predicting the outcomes of metformin therapy, which might be helpful in tailoring diabetes medication. Selenoprotein P (encoded by SELENOP in humans) is a hepatokine that causes impaired insulin secretion and insulin resistance. We found that higher baseline levels of selenoprotein P significantly predicted a hypoglycemic effect and recovery of insulin secretion under metformin therapy. Selenoprotein P might be a novel biomarker for predicting the effect of metformin therapy, and could potentially be the first “tailor‐made” diabetes treatment.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
